Novartis reported a strong Q3 2024 with 9% YoY sales growth, largely driven by its top four drugs. Pluvicto and Leqvio saw significant growth, but investor disappointment stemmed from a revenue ...
Novartis achieved a 12% sales increase and 22% core operating income growth in 2024, marking a strong financial performance. Strategic acquisitions of Calypso Biotech and Argo enhance Novartis' ...
On Thursday, Novartis AG (NYSE:NVS) raised its mid-term sales guidance, increasing its compound annual growth rate (CAGR) target to 6% from 5% for 2023-2028. The upgrade reflects performance from ...
Analyst Etzer Darout of BMO Capital maintained a Hold rating on Novartis (NVS – Research Report), retaining the price target of $118.00. Etzer Darout’s rating is based on a thorough analysis of ...
Novartis (NVS) has announced that it will acquire Tourmaline Bio, Inc. (TRML), a New York-based, publicly traded clinical-stage biopharmaceutical company, for $1.4 billion. The acquisition will add ...
Novartis AG (NYSE:NVS), a global healthcare powerhouse with a market capitalization of $208.27 billion, has recently transformed into a pure-play pharmaceutical company, sharpening its focus on its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback